{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:54:25Z","timestamp":1790834065551,"version":"4.1.0"},"reference-count":22,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1253\/circj.cj-16-1348","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T03:58:53Z","timestamp":1492487933000},"page":"1360-1367","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension"],"prefix":"10.1253","volume":"81","author":[{"given":"Nobuhiro","family":"Tanabe","sequence":"first","affiliation":[{"name":"Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Toho University Omori Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Kajinami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Community Medicine Supporting System, Kyoto University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Center for Global Health and Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Clinical Medicine, Faculty of Medicine, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Medicine, Kyorin University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Pref. Saiseikai Tondabayashi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Faculty of Health Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Yamauchi-Takihara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Tokai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetake","family":"Sasayama","sequence":"additional","affiliation":[{"name":"Uji Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>Eur Heart J<\/i> 2016; 37: 67\u2013119."},{"key":"2","unstructured":"2. Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, Gali\u00e8 N. Treatment of pulmonary hypertension. <i>Lancet Respir Med<\/i> 2016; 4: 323\u2013336."},{"key":"3","unstructured":"3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. <i>Circulation<\/i> 2010; 122: 156\u2013163."},{"key":"4","unstructured":"4. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. <i>J Am Coll Cardiol<\/i> 2015; 65: 1976\u20131997."},{"key":"5","unstructured":"6. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. <i>Chest<\/i> 2012; 142: 448\u2013456."},{"key":"6","unstructured":"7. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial. <i>Chest<\/i> 2012; 142: 1383\u20131390."},{"key":"7","unstructured":"8. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): A randomized controlled trial. <i>Chest<\/i> 2013; 144: 952\u2013958."},{"key":"8","unstructured":"9. Gali\u00e8 N, Humbert M, Vachi\u00e9ry JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. <i>J Am Coll Cardiol<\/i> 2002; 39: 1496\u20131502."},{"key":"9","unstructured":"10. Barst RJ, McGoon M, Mclaughlin V, Tapson V, Oudiz R, Shapiro S, et al. Beraprost therapy for pulmonary arterial hypertension. <i>J Am Coll Cardiol<\/i> 2003; 41: 2119\u20132125."},{"key":"10","unstructured":"11. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, et al. 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. <i>J Pharmacol Exp Ther<\/i> 2007; 322: 1181\u20131188."},{"key":"11","unstructured":"12. Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M. Selexipag: An oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. <i>J Med Chem<\/i> 2015; 58: 7128\u20137137."},{"key":"12","unstructured":"13. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, et al. Selexipag for the treatment of pulmonary arterial hypertension. <i>N Engl J Med<\/i> 2015; 373: 2522\u20132533."},{"key":"13","unstructured":"14. Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist. <i>Am J Cardiovasc Drugs<\/i> 2015; 15: 195\u2013203."},{"key":"14","unstructured":"15. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. <i>N Engl J Med<\/i> 1996; 334: 296\u2013301."},{"key":"15","unstructured":"16. Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. <i>Heart<\/i> 1997; 77: 299\u2013301."},{"key":"16","unstructured":"17. Gali\u00e8 N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. <i>Eur Heart J<\/i> 2004; 25: 2243\u20132278."},{"key":"17","unstructured":"18. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karl\u00f3cai K, Gali\u00e8 N, et al. Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. <i>Eur Respir J<\/i> 2012; 40: 874\u2013880."},{"key":"18","unstructured":"19. D\u2019Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. <i>Ann Intern Med<\/i> 1991; 115: 343\u2013349."},{"key":"19","unstructured":"20. Barst R. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? <i>Int J Clin Pract<\/i> 2010; 64: 23\u201332."},{"key":"20","unstructured":"21. Peacock AJ, Naeije R, Gali\u00e8 N, Rubin L. End-points and clinical trial design in pulmonary arterial hypertension: Have we made progress? <i>Eur Respir J<\/i> 2009; 34: 231\u2013242."},{"key":"21","unstructured":"22. Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). [published erratum appears in <i>Eur Respir J<\/i> 2015; <b>46<\/b>: 1855\u20131856]. <i>Eur Respir J<\/i> 2015; 46: 903\u2013975."},{"key":"22","unstructured":"23. Bruderer S, Okubo K, Mukai H, Mant T, Dingemanse J. Investigation of potential pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy male subjects. <i>Clin Ther<\/i> 2016; 38: 1228\u20131236."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/81\/9\/81_CJ-16-1348\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T03:56:23Z","timestamp":1503719783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/81\/9\/81_CJ-16-1348\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-16-1348","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}